LIANY.US LianBio

Healthcare Biotechnology USA Stocks
0.0490 USD
Close of Nov 15, 2026
0.0210 0.1770
Market cap
USD 5.35M
P/E
-
P/B
0.03x
ROE
23.9%
Dividend yield
886.05%
Fundamental score
-

Ratios use the latest price and the fiscal year ending Sep 2025.

Is LIANY.US undervalued?

Graham number

The Graham number of LianBio cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

LianBio fundamental analysis

No fundamental analysis for LianBio yet.

LianBio stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About LianBio

LianBio, operates as a biotechnology company in China and other Asian countries. It offers medicines for cardiovascular, oncology, ophthalmology, and inflammatory disease indications. The company develops mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, which is in Phase 3 EXPLORER-CN trial; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease, which is in Phase 3 LIBRA trial; NBTXR3 for the treatment of head and neck squamous ce…

Full company profile